- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Juvenile idiopathic arthritis (JIA) |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Consider whether the use of an NSAID is justified.When celecoxib is prescribed to children at risk: verify renal function prior to the start and within the first week after starting.
GFR 30-50 ml/min/1.73 m2
Consider whether the use of an NSAID is justified.When celecoxib is prescribed to children at risk: verify renal function prior to the start and within the first week after starting.
GFR 10-30 ml/min/1.73 m2
Consider whether the use of an NSAID is justified.When celecoxib is prescribed to children at risk: verify renal function prior to the start and within the first week after starting.
GFR < 10 ml/min/1.73 m2
A general recommendation is not given.Clinical consequences
Risk-factors are: heart failure, liver cirrhosis, nephrotic syndrome, chronic kidney disease, causes leading to dehydration (e.g. summer heat), use of other drugs decreasing renal function, like diuretics or RAAS inhibitors.
NSAIDs (including COX-2 inhibitors) can cause acute renal failure by decreasing renal perfusion (by hypovolaemia). Normally, an increased prostaglandin synthesis in the kidneys prevents a rapid decrease in renal perfusion; however, NSAIDs disturb this compensating mechanism. Decreased renal perfusion also leads to water and salt retention, resulting in the occurrence or worsening of hypertension and heart failure.
Patients on dialysis
Haemodialysis / continuous venovenous haemodialysis or haemo(dia)filtration:
- residual kidney function (urine production) PRESENT: avoid use to save residual kidney function
- residual kidney function (urine production) NOT PRESENT: avoidance is not necessary
Patients undergoing dialysis have a higher bleeding risk, probably related to an abnormal platelet function. The bleeding risk can be increased by the use of low molecular weight heparines at the start of haemodialysis to prevent coagulation in the extracorporeal circulation.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Headaches, fever, abdominal pain, nausea, arthralgia, diarrhoea and vomiting.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
In exceptional cases, varicella can lead to serious infectious complications of the skin and soft tissues. To date, it cannot be ruled out that NSAIDs contribute to the worsening of these infections. It is therefore recommended not to use celecoxib in cases of varicella (Prescrire Internat 2010).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Acetic acid derivatives and related substances | ||
|---|---|---|
| M01AB05 | ||
| M01AB01 | ||
| Oxicams | ||
|---|---|---|
| M01AC01 | ||
| Propionic acid derivatives | ||
|---|---|---|
| M01AE14 | ||
| M01AE01 | ||
| M01AE02 | ||
| Fenamates | ||
|---|---|---|
| M01AG01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Pfizer, Product Label Celebrex (USA)- dec 2008, www.accessdata.fda.gov
- Acino, SmPC Celecoxib Acino 100 / 200 mg Hartkapseln (86065.00.00 / 86066.00.00), 01/2017
- Pfizer, SmPC CELEBREX® 100 mg/200 mg (48802.00.00 / 48802.01.00), 11/2017
- MMI, Gelbe Liste I Online, 06/2018
- AbZ, SmPC Celecoxib 100/200 mg Hartkapseln (83817.00.00/83818.00.00), 02/2016
- Pfizer, SmPC Celecoxib 100/200 mg Hartkapseln (48802.00.00/48802.01.00), 11/2017
- <No author listed>, Varicella, herpes zoster and nonsteroidal anti-inflammatory drugs: serious cutaneous complications., Prescrire Internat, 2010, 19, 72-73
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
